It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Ryan Kessinger, Sr., 5-10, S, Jake Starr, Sr., 6-1, OH, Mario Romagni, Sr., 6-0, OH, Tony Masters, Sr., 6-5, MH, Maddox Fuenes, So., 6-5, MH, Levi Rohl, Sr., 5-11, OPP, Trent Hornak, Sr., 5-9, L ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

As the guests of honor, they walked down a red carpet, free of kids for the night, to enjoy time with others in the community ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

Tyler ISD Police Department arrested three employees on Friday. Dr. Marty Crawford said it did involve a student with ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Erika Adams is the deputy editor of Eater Northeast, covering restaurant news and dining trends in Boston, Philadelphia, D.C.